TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16526415

Group type: EXPERIMENTAL
Intervention: Dietary phytoestrogens (soy and unrefined grain products)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Various dietary patterns rich in phytoestrogens
Number of subjects: 0
Study: 11981151

Group type: EXPERIMENTAL
Intervention: Clot Signature Analyzer collagen‐induced thrombus formation (CITF) assay
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Clot Signature Analyzer CITF
Number of subjects: 57
Study: 10371877

Group type: EXPERIMENTAL
Intervention: Zinc citrate dentifrice (2% zinc citrate and 0.76% sodium monofluorophosphate in a silica base)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control dentifrice (0.76% sodium monofluorophosphate in a silica base)
Number of subjects: 75
Study: 8584682

Group type: EXPERIMENTAL
Intervention: Fluspirilene 0.5 mg per week
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Fluspirilene 1.0 mg per week
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Fluspirilene 1.5 mg per week
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Test therapy (initial response after 2 weeks)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Decreases in somatic anxiety, psychic anxiety, and Hamilton-total-score
Number of subjects: 106
Study: 2093885

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 637427

Group type: EXPERIMENTAL
Intervention: High-fiber diet (20 g of crude fiber)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low-fiber diet (3 g of crude fiber)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 8
Study: 31318075

Group type: EXPERIMENTAL
Intervention: Family therapy with lenient definitions of remission
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Family therapy with stringent definitions of remission
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Comparison of 11 definitions of remission
Number of subjects: 106
Study: 28914104

Group type: EXPERIMENTAL
Intervention: Weight loss intervention (diet + exercise)
Number of subjects: 180
Study: 25774836

Group type: EXPERIMENTAL
Intervention: Multidisciplinary group clinic appointments
Number of subjects: 198

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 198
Study: 23923010

Group type: EXPERIMENTAL
Intervention: Functional tumors (positive ER protein expression and gene ratio normal or gain/amplification)
Number of subjects: 1010

Group type: COMPARATOR
Intervention: Paclitaxel therapy
Number of subjects: 1010

Group type: COMPARATOR
Intervention: Gene Functional profile
Number of subjects: 1010
Study: 21568077

Group type: EXPERIMENTAL
Intervention: 0.2% brimonidine
Number of subjects: 27

Group type: COMPARATOR
Intervention: 0.5% apraclonidine
Number of subjects: 27
Study: 19458055

Group type: EXPERIMENTAL
Intervention: Satraplatin administered orally at 80 mg/m² once daily for 5 consecutive days every 5 weeks (fasted state)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Satraplatin administered in fed state on day 1 and day 5 of cycle 1
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Satraplatin administered in fasted state for subsequent cycles
Number of subjects: 17
Study: 16751782

Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 195

Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 195
Study: 15641642

Group type: EXPERIMENTAL
Intervention: Acute poisonings via ingestion
Number of subjects: 71589

Group type: EXPERIMENTAL
Intervention: Acute poisonings via dermal exposure
Number of subjects: 71589

Group type: EXPERIMENTAL
Intervention: Acute poisonings via inhalation
Number of subjects: 71589

Group type: EXPERIMENTAL
Intervention: Intentional poisoning
Number of subjects: 71589

Group type: EXPERIMENTAL
Intervention: Pharmaceutical poisons
Number of subjects: 71589

Group type: EXPERIMENTAL
Intervention: Chemical poisons
Number of subjects: 71589

Group type: EXPERIMENTAL
Intervention: Natural toxins
Number of subjects: 71589

Group type: EXPERIMENTAL
Intervention: Seasonal trends in poisonings
Number of subjects: 71589
Study: 11391226

Group type: EXPERIMENTAL
Intervention: 1 mg/day RAD
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: 2 mg/day RAD
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: 4 mg/day RAD
Number of subjects: 103
Study: 9266292

Group type: EXPERIMENTAL
Intervention: Palliative physical treatment
Number of subjects: 136
Study: 8104238

Group type: EXPERIMENTAL
Intervention: Carvedilol with moderate sodium restriction
Number of subjects: 19

Group type: COMPARATOR
Intervention: Carvedilol without sodium restriction
Number of subjects: 19
Study: 2878953

Group type: EXPERIMENTAL
Intervention: Tertatolol 5 mg orally
Number of subjects: 20

Group type: COMPARATOR
Intervention: Propranolol 160 mg orally
Number of subjects: 20
Study: 30114973

Group type: EXPERIMENTAL
Intervention: Isometric leg press training at S-MTU (knee angle 145°)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Isometric leg press training at L-MTU (knee angle 85°)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Both training groups (S-MTU and L-MTU)
Number of subjects: 15
Study: 29776410

Group type: EXPERIMENTAL
Intervention: Counsellor-supported disclosure model (CSD)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Standard HIV testing & counselling (HTC)
Number of subjects: 276
Study: 28868876

Group type: EXPERIMENTAL
Intervention: Quyu Huatan decoction
Number of subjects: 93

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 93
Study: 23674271

Group type: EXPERIMENTAL
Intervention: First Leaf (FL; composed of blackcurrant extract powder, lactoferrin and lutein)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cassis Anthomix 30 (CAM30; blackcurrant extract powder)
Number of subjects: 30
Study: 22545801

Group type: EXPERIMENTAL
Intervention: Online intervention focusing on internalized heterosexism (IH) reduction
Number of subjects: 367

Group type: COMPARATOR
Intervention: Control condition focusing on stress management
Number of subjects: 367
Study: 20347079

Group type: EXPERIMENTAL
Intervention: Crinone vaginal gel
Number of subjects: 468

Group type: COMPARATOR
Intervention: Intramuscular progesterone (IMP)
Number of subjects: 468
Study: 18541303

Group type: EXPERIMENTAL
Intervention: Alcohol ingestion (0.59+/‐0.07 g/kg body weight)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Juice ingestion
Number of subjects: 13
Study: 17288066

Group type: EXPERIMENTAL
Intervention: CNO enrollment
Number of subjects: 0
Study: 12621096

Group type: EXPERIMENTAL
Intervention: Cycled (day-night lighted room)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dim (dimly lighted room)
Number of subjects: 40
Study: 10962113

Group type: EXPERIMENTAL
Intervention: Hyperglycaemic clamp at 10 mmol/l in non-diabetic twins
Number of subjects: 16

Group type: COMPARATOR
Intervention: Baseline measurements in non-diabetic twins
Number of subjects: 16

Group type: COMPARATOR
Intervention: Baseline measurements in diabetic twins
Number of subjects: 16
Study: 9068306

Group type: EXPERIMENTAL
Intervention: Dietary health education programme
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Standard health education as delivered by health visitors
Number of subjects: 1000
Study: 8392235

Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 3529352

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Conventional insulin therapy (CIT)
Number of subjects: 11
Study: 28752736

Group type: EXPERIMENTAL
Intervention: Alcoholic skin disinfection before PNC removal
Number of subjects: 200

Group type: COMPARATOR
Intervention: Without alcoholic skin disinfection
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: With alcoholic skin disinfection
Number of subjects: 200
Study: 26215222

Group type: EXPERIMENTAL
Intervention: Lymphocytic infiltration score 3 (LI score 3)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: CD3 staining score 3
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: CD20 staining score 3
Number of subjects: 195
Study: 24627256

Group type: EXPERIMENTAL
Intervention: Early feeding
Number of subjects: 120

Group type: COMPARATOR
Intervention: Traditional feeding
Number of subjects: 120
Study: 23859673

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg IV qd followed by 400 mg PO qd
Number of subjects: 116

Group type: COMPARATOR
Intervention: Ampicillin-sulbactam 1.5 g IV qid followed by 750 mg PO q12h
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 116

Group type: COMPARATOR
Intervention: Ampicillin-sulbactam
Number of subjects: 116

Group type: COMPARATOR
Intervention: Ampicillin-sulbactam therapy
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Time to ED presentation >24 h
Number of subjects: 116
Study: 20572416

Group type: EXPERIMENTAL
Intervention: Positional device (PD)
Number of subjects: 38

Group type: COMPARATOR
Intervention: CPAP (10 ± 3 cm H2O)
Number of subjects: 38
Study: 18783303

Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 1987

Group type: COMPARATOR
Intervention: FU+LV
Number of subjects: 1987
Study: 16600508

Group type: EXPERIMENTAL
Intervention: Oxycodone (15 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Morphine (30 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 14596361

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg + Hydrochlorothiazide 12.5 mg
Number of subjects: 40
Study: 10976273

Group type: EXPERIMENTAL
Intervention: Capecitabine (Xeloda)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Paclitaxel (Taxol)
Number of subjects: 41
Study: 8971294

Group type: EXPERIMENTAL
Intervention: 10 g sucralfate
Number of subjects: 40

Group type: COMPARATOR
Intervention: 100 mg hydrocortisone
Number of subjects: 40
Study: 30168581

Group type: EXPERIMENTAL
Intervention: Simulated Clinical Placement (SCP) - 40 hours
Number of subjects: 570

Group type: COMPARATOR
Intervention: Traditional Clinical Placement (TCP) - 40 hours
Number of subjects: 570
Study: 27040041

Group type: EXPERIMENTAL
Intervention: Silymarin (140 mg every 8 hours for 2 months)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 50
Study: 25400056

Group type: EXPERIMENTAL
Intervention: Photodynamic antimicrobial therapy with Fufanghuangbai liquid wet dressing and semiconductor laser irradiation (20 min twice daily for 7 days)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group with Fufanghuangbai liquid for external application
Number of subjects: 42
Study: 23715447

Group type: EXPERIMENTAL
Intervention: Intraligamentous injections with 4% articaine with epinephrine
Number of subjects: 36
Study: 20925920

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic training (150 mins/week at 60%-70% VO₂peak for 16 weeks)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Moderate to high-intensity aerobic training (150 mins/week at 60%-100% VO₂peak for 16 weeks)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Attention control (progressive stretching for 16 weeks)
Number of subjects: 174
Study: 18622840

Group type: EXPERIMENTAL
Intervention: Vacuum-formed rigid dressing (ORD)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conventional rigid dressing (C)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 27
Study: 16324243

Group type: EXPERIMENTAL
Intervention: Stark cesarean section (Group A)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Longitudinal incision cesarean section (Group B)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Pfannenstiel incision cesarean section (Group C)
Number of subjects: 353
Study: 11887942

Group type: EXPERIMENTAL
Intervention: Radiologists' readings using image features from CT and MR imaging
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Statistical prediction rules (SPRs) using features from all modalities
Number of subjects: 146

Group type: COMPARATOR
Intervention: Contrast-enhanced MR imaging and contrast-enhanced CT
Number of subjects: 146
Study: 10407840

Group type: EXPERIMENTAL
Intervention: Psychoeducational training and cognitive psychotherapy for patients and counseling for their key persons
Number of subjects: 191
Study: 7743788

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg/day
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Overall adherence
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Exclusion of poor run-in adherers
Number of subjects: 431
Study: 2160781

Group type: EXPERIMENTAL
Intervention: Double Burst Stimulation (DBS) at 50 mA
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Double Burst Stimulation (DBS) at 30 mA
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Double Burst Stimulation (DBS) at 20 mA
Number of subjects: 21

Group type: COMPARATOR
Intervention: Train-of-Four (TOF) at 50 mA
Number of subjects: 21

Group type: COMPARATOR
Intervention: Train-of-Four (TOF) at 30 mA
Number of subjects: 21

Group type: COMPARATOR
Intervention: Train-of-Four (TOF) at 20 mA
Number of subjects: 21
Study: 7026344

Group type: EXPERIMENTAL
Intervention: Cimetidine 1 g/day (short-term)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Pirenzepine 75 mg/day (short-term)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (short-term)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg at bedtime (long-term)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Pirenzepine 30 mg at bedtime (long-term)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (long-term)
Number of subjects: 200
Study: 30580530

Group type: EXPERIMENTAL
Intervention: Blood cardioplegia
Number of subjects: 70

Group type: COMPARATOR
Intervention: Crystalloid cardioplegia (control)
Number of subjects: 70
Study: 27941358

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 26553006

Group type: EXPERIMENTAL
Intervention: Phytosterols and inulin-enriched soymilk (2 g/day of phytosterols and 10 g/day of inulin)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Standard soymilk (control)
Number of subjects: 240
Study: 23428186

Group type: EXPERIMENTAL
Intervention: BoNT‐A injections
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 73
Study: 21875640

Group type: EXPERIMENTAL
Intervention: POs-Ca chewing gum
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: POs-Ca+F chewing gum
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo chewing gum
Number of subjects: 36
Study: 19688627

Group type: EXPERIMENTAL
Intervention: Resistant Starch (RS) 25 g daily for 14 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Wheat Bran (WB) 25 g daily for 14 days
Number of subjects: 14
Study: 17656071

Group type: EXPERIMENTAL
Intervention: Antisaccade task performance in UHR patients
Number of subjects: 35

Group type: COMPARATOR
Intervention: Antisaccade task performance in recent-onset schizophrenia patients
Number of subjects: 35

Group type: COMPARATOR
Intervention: Antisaccade task performance in healthy controls
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Baseline antisaccade error rate in UHR patients who transitioned to psychosis
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Spatial working memory function in UHR patients
Number of subjects: 35
Study: 15449974

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 50693

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 50693
Study: 11264688

Group type: EXPERIMENTAL
Intervention: Non-Chinese individuals
Number of subjects: 2096

Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 2096
Study: 8988907

Group type: EXPERIMENTAL
Intervention: 20 mg Zn as zinc methionine
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: 20 mg Zn + 20 mg Fe
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study: 8506732

Group type: EXPERIMENTAL
Intervention: Low-dose radiotherapy (5 x 2 Gy)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High-dose radiotherapy (10 x 2 Gy or 5 x 3.5 Gy)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low-dose vs High-dose radiotherapy
Number of subjects: 60
Study: 3651109

Group type: EXPERIMENTAL
Intervention: Kallikrein 100 K.U. t.i.d. for 120 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Vitamin E 100 mg t.i.d. for 120 days
Number of subjects: 16
Study: 29984567

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) based on NeckPix©, 4 sessions, 1-week duration
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) based on Tampa Scale of Kinesiophobia (TSK), 4 sessions, 1-week duration
Number of subjects: 30

Group type: COMPARATOR
Intervention: Motor training (10 sessions, 5-week duration)
Number of subjects: 30
Study: 28937784

Group type: EXPERIMENTAL
Intervention: Lacertus fibrosus
Number of subjects: 10

Group type: COMPARATOR
Intervention: Achilles tendon
Number of subjects: 10
Study: 26775476

Group type: EXPERIMENTAL
Intervention: General anesthesia combined EA anesthesia group (Group B)
Number of subjects: 54

Group type: COMPARATOR
Intervention: General anesthesia group (Group A)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 54
Study: 24119994

Group type: EXPERIMENTAL
Intervention: Insecticide-treated bed nets (ITN)
Number of subjects: 916

Group type: COMPARATOR
Intervention: Anopheles mosquito biting behavior
Number of subjects: 916

Group type: COMPARATOR
Intervention: Anopheles annularis
Number of subjects: 916
Study: 21398582

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro manipulation of Programmed Death‐1 and 2B4 pathways
Number of subjects: 0
Study: 18314433

Group type: EXPERIMENTAL
Intervention: Switch to a second, different SSRI (paroxetine, citalopram, or fluoxetine, 20‐40 mg)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Switch to venlafaxine (150‐225 mg)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Switch to a different SSRI plus cognitive behavioral therapy
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Switch to venlafaxine plus cognitive behavioral therapy
Number of subjects: 334

Group type: COMPARATOR
Intervention: Medication switch alone
Number of subjects: 334
Study: 15864239

Group type: EXPERIMENTAL
Intervention: Tissue Doppler Imaging (TDI)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (age-matched healthy volunteers)
Number of subjects: 47
Study: 12202662

Group type: EXPERIMENTAL
Intervention: UFT (300 mg/m²/d) and LV (90 mg/d) for 28 days every 35 days
Number of subjects: 380

Group type: COMPARATOR
Intervention: 5-FU (425 mg/m²/d) and LV (20 mg/m²/d) IV for 5 days every 35 days
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: UFT/LV
Number of subjects: 380

Group type: COMPARATOR
Intervention: 5-FU/LV
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: UFT/LV and 5-FU/LV
Number of subjects: 380
Study: 10599909

Group type: EXPERIMENTAL
Intervention: Full-mouth scaling plus systemic metronidazole and amoxicillin and supragingival irrigation with chlorhexidine digluconate
Number of subjects: 48

Group type: COMPARATOR
Intervention: Full-mouth scaling alone (control)
Number of subjects: 48
Study: 7495241

Group type: EXPERIMENTAL
Intervention: Multivitamin and multimineral supplements
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3000
Study: 1683819

Group type: EXPERIMENTAL
Intervention: Nitrous oxide, 70%
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no nitrous oxide)
Number of subjects: 56
Study: 6130074

Group type: EXPERIMENTAL
Intervention: Buspirone 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Buspirone 20 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Alcohol (1 g/kg) with Buspirone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lorazepam 2.5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lorazepam with Alcohol
Number of subjects: 12
Study: 30995972

Group type: EXPERIMENTAL
Intervention: Atrasentan 0·75 mg orally daily
Number of subjects: 2648

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2648
Study: 30768615

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP) mass drug administration (MDA)
Number of subjects: 8445

Group type: COMPARATOR
Intervention: Control villages (no early MDA)
Number of subjects: 8445
Study: 28103942

Group type: EXPERIMENTAL
Intervention: Fluralaner topical solution
Number of subjects: 224

Group type: COMPARATOR
Intervention: Fipronil/(S)-methoprene combination
Number of subjects: 224
Study: 25795029

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg once daily
Number of subjects: 52
Study: 23173698

Group type: EXPERIMENTAL
Intervention: Lead-in twice-daily interferon-β/ribavirin therapy (IFN-β)
Number of subjects: 46

Group type: COMPARATOR
Intervention: PEG-IFN/ribavirin therapy (PEG)
Number of subjects: 46
Study: 21600384

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study: 19568011

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BtX‐A) injection
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sterile saline solution (placebo)
Number of subjects: 52
Study: 16956684

Group type: EXPERIMENTAL
Intervention: 30‐36 Gy whole brain irradiation (WBI)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Quality of life and neurocognitive function data
Number of subjects: 19
Study: 15059333

Group type: EXPERIMENTAL
Intervention: S + R (surgery plus radiotherapy)
Number of subjects: 495

Group type: COMPARATOR
Intervention: S (surgery alone)
Number of subjects: 495
Study: 11711490

Group type: EXPERIMENTAL
Intervention: Estrogen supplementation (estradiol valerate 1 mg daily; n=7)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (n=5)
Number of subjects: 12
Study: 9158556

Group type: EXPERIMENTAL
Intervention: Endurance training 3 days/week (ET3) for 6 months
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Endurance training 5 days/week (ET5) for 6 months
Number of subjects: 67

Group type: COMPARATOR
Intervention: Stretching/flexibility (SF3) for 6 months
Number of subjects: 67
Study: 8427243

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61